Skip to main content
Contact Us
Subscribe
E-Edition
33°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cabaletta Bio, Inc. - Common Stock
(NQ:
CABA
)
2.380
+0.070 (+3.03%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cabaletta Bio, Inc. - Common Stock
< Previous
1
2
3
Next >
Cabaletta Bio to Participate in Upcoming Investor Conferences in December
November 26, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
November 18, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
November 14, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
November 06, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 12/8
December 08, 2023
Via
Investor Brand Network
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 11/9
November 09, 2023
Via
Investor Brand Network
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
September 25, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
August 28, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 10/24
October 24, 2023
Via
Investor Brand Network
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 10/23
October 23, 2023
Via
Investor Brand Network
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
July 02, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
June 14, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
May 29, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
May 15, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 13, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 21, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
March 20, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
February 27, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
February 01, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
January 08, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 28, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform
November 06, 2023
From
Cellares
Via
Business Wire
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
November 06, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November
October 30, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201
October 02, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
September 19, 2023
From
Cabaletta Bio
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.